Αρχειοθήκη ιστολογίου

Τρίτη 2 Αυγούστου 2016

In-vitro Anti-Leishmanial Potential of Peptide Drug Hirudin

Abstract

Hirudin is clinically an important drug used for the treatment of cardiac diseases, but has never been elucidated for anti-leishmanial potential. The present study was designed to determine the therapeutic utility of hirudin against leishmaniasis. Binding affinities of 28 potent proteinase inhibitors were screened computationally against leishmanolysin (GP63), out of which, hirudin exhibited higher binding affinity with GP63 and good expected IC50 values. Experimentally, hirudin showed most promising activity against promastigote and axenic amastigote forms of leishmanial parasites with IC50 values of 0.60±0.36 μg/ml and 0.43±0.23 μg/ml, respectively in a dose and time-dependent assay. The cytotoxicity assay revealed no adverse effects on human macrophages with LD50 value of 860.11±53.44 μg/ml. Hirudin caused leishmanial cell death mainly by apoptosis and membrane permeability. In spite of the basic knowledge obtained, hirudin mechanism is considerably less prone to the induction of resistance than classical drugs. Collectively, the current study fosters further studies for the hirudin as new anti-leishmania lead with a new mode of action.

This article is protected by copyright. All rights reserved.



from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2aZR1tU
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου